Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Viatris’ Effexor Approved in Japan for Generalized Anxiety Disorder | Contract Pharma

What are you searching for?

Sign in
Trials & Filings

Viatris’ Effexor Approved in Japan for Generalized Anxiety Disorder

Effexor becomes the first approved treatment option in Japan for GAD.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma
Viatris

Viatris Inc., a global healthcare company, received approval from Japan’s Ministry of Health, Labour and Welfare (MHLW) for Effexor SR 37.5 mg / 75 mg capsules (venlafaxine hydrochloride), a serotonin-noradrenaline reuptake inhibitor for the treatment of adults with generalized anxiety disorder (GAD). With the MHLW’s decision, Effexor becomes the first approved treatment option in Japan for GAD. Effexor is currently approved in Japan for the indication of major depressive disorder in adults.

The approval of Effexor for GAD is based on a Phase 3 placebo-controlled, randomized, double-blind, multicenter study of venlafaxine in patients with GAD conducted in Japan. The Study achieved its primary objective of superiority of anxiolytic effects of venlafaxine compared to placebo at 8 weeks, based on the change in the Hamilton Anxiety Rating Scale (HAM-A) total score from baseline. All seven secondary efficacy endpoints as defined by the trial protocol were met. Effexor was generally well tolerated with a profile consistent with its known safety profile in non-Japanese patients. 

These results and the results of a long-term extension study of venlafaxine in Japanese outpatients with GAD were included as part of the applications for approval. Effexor is currently approved to treat GAD in more than 80 countries outside of Japan.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics